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Abstract
Background: As the magnitude of the experiment increases, it is common to combine various types of
microarrays such as paired and non-paired microarrays from different laboratories or hospitals. Thus, it is important
to analyze microarray data together to derive a combined conclusion after accounting for heterogeneity among
data sets. One of the main objectives of the microarray experiment is to identify differentially expressed genes
among the different experimental groups. We propose the linear mixed effect model for the integrated analysis of
the heterogeneous microarray data sets.
Results: The proposed linear mixed effect model was illustrated using the data from 133 microarrays collected at
three different hospitals. Though simulation studies, we compared the proposed linear mixed effect model
approach with the meta-analysis and the ANOVA model approaches. The linear mixed effect model approach was
shown to provide higher powers than the other approaches.
Conclusions: The linear mixed effect model has advantages of allowing for various types of covariance structures
over ANOVA model. Further, it can handle easily the correlated microarray data such as paired microarray data and
repeated microarray data from the same subject.
Background
Microarray technology has important applications in
pharmaceutical and clinical research. For example,
microarrays can be used to identify tumor-related genes
and targets for therapeutic drugs. In microarray experi-
ments, the identification of differentially expressed genes
(DEG) is an important issue. Statistical test procedures
have served as useful tools for identifying the DEGs
which can be candidate genes for a specific disease or
can be used for the further analysis such as clustering
analysis and gene regulatory network construction.
As the cost of producing microarrays has become
lower costs and the importance of replication in micro-
array experiments has been demonstrated by many
researchers [1], replicated microarrays are commonly
used in microarray experiments. In order to handle
replicated microarrays, many statistical test procedures
have been developed, such as t-statistics, to identify
DEGs between two groups [2]. The analysis of variance
(ANOVA) model approach was proposed to identify
DEGs among multiple groups [3]. In addition, many sta-
tistical models have been proposed to identify the DEGs
on replicated microarrays [4-11].
When the magnitude of a microarray experiment
increases, it is common to use the same type of micro-
arrays from different laboratories or hospitals. Thus, it is
important to analyze microarray data together to derive
a combined conclusion after accounting for the differ-
ences. Recently, statistical approaches based on meta-
analysis have been proposed in order to combine inde-
pendent and heterogeneous microarray studies [12-15].
In these approaches, microarrays were classified into
several independent groups and integration methods to
analyze microarray data sets from different laboratories
were proposed. The key idea of meta-analysis is to com-
bine summary statistics from each study in which signif-
icant levels (p-values) and effect sizes are commonly
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be homogeneous within the data set. When there are
microarray-specific covariates such as gender and smok-
ing status, meta-analysis can be less effective.
Shen et al. (2004) introduced the probability of
expression (POE) and proposed a method to estimate
the POE using MCMC [16]. The POE is the scale-free
measure transformed from raw gene expression defined
by the difference between probabilities of over- and
under-expressed gene expression. Using the POE, the
gene expressions of heterogenous microarray experi-
ments can be uniquely scaled from -1 and 1 and com-
bined easily. Choi et al. (2007) proposed EM algorithm
to estimate the POE instead of MCMC, which can
reduce the estimation time of the POE [17]. Standar-
dized POE can combine multiple microarray data sets,
however, the POE method canb em o r ee f f i c i e n tw h e n
the microarray-specific covariates are applied.
Park et al. [18] proposed a two-stage ANOVA model
approach for the integrated analysis, which uses the
ANOVA model with controlling variables for additional
variability of heterogeneous microarray studies. The
usual ANOVA model was extended to account for an
additional variability resulting from many confounding
variables. When variability among data sets is relatively
small, the ANOVA model is effective. Otherwise, the
ANOVA model is not recommended. Further, when the
microarrays are correlated, the ANOVA model cannot
handle such correlation appropriately, because it
requires the independence of samples. Therefore, corre-
lated microarray data can violate the assumption of the
ANOVA model and thus the extended model to allow
for various types of covariance structure of errors is
needed.
In this paper, we propose the linear mixed effect
(LMe) model for the integrated analysis of the heteroge-
neous microarray data sets. The LMe model contains
various random effects which effectively account for the
heterogeneous variability in the data from many differ-
ent sources. Further, the LMe model has advantages of
allowing for various types of covariance structures over
meta-analysis and ANOVA model approaches. Thus, it
can handle easily the correlated microarray data such as
paired and non-paired microarray data. The proposed
method is illustrated using the liver cancer microarray
data sets obtained from three different hospitals [14].
Materials and methods
Four independent microarray data sets were generated
from three hospitals using two different chips [15]. The
first chip, C1, contains 10,336 human cDNA probes that
were verified by single pass sequencing. The second
chip, C2, contains 10,368 human cDNA probes. Two
chips shared the common 9,984 cDNA probes. The
chips were cDNA chips with two-colors, where the way
of labeling samples and controls is described in Choi et
al. (2004). A further detailed description of the chips
has been uploaded to the Gene Expression Omnibus
(GEO) site (http://www.ncbi.nlm.nih.gov/geo/) with
GEO accession number GPL2911.
The chip type (1 and 2), labeling scheme, hospital and
number of samples are shown in this table. Here, the
data were normalized by locally weighted scatterplot
smoothing (LOWESS; Cleveland, 1979). For LOWESS
normalization, the value of the span parameter was 0.75
and the tricubic function was used as a weight function.
For robustness analysis, Tukey’s biweight function was
used [18]. Hepatocellular carcinoma (HCC) and adjacent
control (normal) samples were obtained with informed
c o n s e n tf r o mp a t i e n t sa tt h r e eh o s p i t a l s .A l lt h eH C C
samples were hepatitis B virus (HBV) positive. Sample
preparation, microarray hybridizations, and fluorescence
signal acquisitions were carried out independently at
each institution according to similar but not identical
experimental protocols and laboratory conditions.
Table 1 summarizes the descriptive information for
the microarray experiment. Thirty two microarrays were
produced from 17 patients in Hospital A yielding data
set D1. A pair of microarrays for each patient were pro-
duced from two cDNA samples: one from the HCC
sample and the other from the control(normal) sample.
In Hospital A, fifteen pairs of microarrays and two indi-
vidual microarrays were produced. Forty six microarrays
were produced from 23 patients in Hospital B yielding
data set D2. Fifty five microarrays were produced from
43 patients in Hospital C. Only twelve pairs of microar-
rays and 37 individual microarrays were produced. Chip
C2 was used only on 21 microarrays from 13 patients in
Hospital C. Other microarrays were produced by Chip
C1. Microarrays from Hospital C were divided into two
data sets (D3 and D4) according to the chip type. All
microarray data were obtained using the reference
design with the placenta as the reference.
The LMe models
Suppose there are H multiple data sets denoted by h =
1, …, H. There are nh patients for the hth data set. In
our study, H = 4 and treatment groups consist of two
levels denoted by k = T, C,w h e r eo n e( k = T)i st h e
tumor tissue group and the other (k = C) is the control
tissue group. For the paired observations, k has two
values T and C. For the non-paired observation, k has
only one value of T or C. Assume there are N common
probes on each chip for all data sets. We denote genes
by l (= 1,…, N).The linear mixed effects (LMe) model
consists of both fixed effects and random effects. The
LMe model for the lth gene is given by
Yhil = Xhilbl + Zhilbhil + εhil,
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where Yhil is a response vector for the ith subject
(patient) of the hth data set, bl is the fixed effect para-
meter vector, bhil is the random effect parameter vector,
and εhil is the error vector. Random effects and errors are
assumed to be independent and normally distributed:
bhil ~ N(0, Fl), εhil ~ N(0, Is
2). (2)
The variance of random effects Fh can have several
forms. When the off-diagonal terms are zero, then the
random effects are uncorrelated. Otherwise, they are
correlated. By allowing different forms of Fh,w ec a n
model variability among samples efficiently. When there
are no random effects, say Zhil =0 ,t h eL M em o d e l s
become equivalent to the ANOVA models.
For the liver cancer data, there are three fixed effects:
treatment, hospital, and chip type. The LMe model is
given by following equation:



































































where l =1 , …, 9984, h =1 , …,4 ,bTl represents the
treatment effect of differences between tumor tissue
and control tissue, bCl represents the effect of differ-
ences between two chips, and two parameters, bH1l
and bH2l,r e p r e s e n tt h ee f f e c to fd i f f e r e n c e sa m o n g
hospitals.
Types of covariance structure
The most general form of covariance matrix in the LMe
models assumes the covariance matrix of gene expres-
sions within each data set is unstructured and differs
among data sets. However, this covariance matrix
requires many parameters to be estimated, which could
result in a possible loss of power. Therefore, we need to
consider simplified forms of the covariance matrices of
bhil. We consider four types of covariance forms for the
integrated analysis of microarray data. For simplicity, we
start with the case when the data consist of all paired
observations.
Paired microarrays
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2. Type 2: One common unstructured covariance
matrix for all data sets Covariance matrix of bhil:



















3. Type 3: Compound symmetry covariance matrix
with different variance parameter for each data set bhil
has only one component bhil and its variance is given by
Var b h H hil h () , ,, ==  
2 1 
4. Type 4: One common compound symmetry covar-
iance matrix with the same variance parameter for all
data sets bhil has only one component bhil and its var-
iance is given by
Var bhil c () = 
2
Type 2 assumes the covariance matrix of gene expres-
sions within each data set is unstructured like Type 1
but it is the same over the data sets, which is a simpli-
fied form of Type 1. Type 3 assumes each covariance
matrix within the data set is compound symmetric and
differs over the data sets. Type 4 is simplified version of
Type 3 assuming the same covariance matrix over the
data sets.
For all types of covariance structure, the variance of




For the non-paired observation, the dimension of Yhil
becomes one. The LMe allows only a scalar random
effect. That is, bhil has only one component bhikl.F o r
example, Type 1 assumes
Table 1 Descriptive information for the liver cancer microarray data
Data set ID Hospital Chip type Number of paired samples Number of non-paired samples Total number of samples
tumor control tumor control
D1 A C1 15 15 1 1 32
D2 B C1 23 23 0 0 46
D3 C C1 4 4 25 1 34
D4 C C2 88 4 1 2 1
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LMe model parameters can be estimated via maximum
likelihood estimation. The DEGs can be identified by
testing whether bTl = 0 or not. LMe models also suffer
from the multiple testing problem. We apply the FDR
adjustment method proposed by Benjamini et al.[19].
Results
Analysis of the liver cancer microarray data
We applied the integrated analysis using LMe models,
two-stage ANOVA model, and meta-analysis to liver
cancer data. The LMe model is given in Equation 3. We
fit this LMe model by assuming that bhil has the covar-
iance structure of Types 1 to 4. These four models are
denoted by M1, M2, M3, and M4, respectively. The last
LMe model M5 assumes no random effects and is
expected to provide similar results to the two-stage
ANOVA model.
Table 2 shows the number of DEGs for the given
FDRs. A much larger number of genes were identified
by integrated analyses. When FDR is controlled by 5%,
the number of DEGs on each individual microarray data
set D1 to D4 are only 0, 38, 0, and 0, respectively [18].
However, the number of identified genes by meta-analy-
sis, ANOVA model, five LMe models are 197, 145, 214,
543, 589, 375, and 114, respectively. The number of sig-
nificant genes varied across methods. The smallest num-
ber of genes was selected by the LMe model M5 which
requires the independent assumption between the paired
microarrays. A similar number of genes was selected in
meta-analysis and ANOVA model using the permuta-
tion tests. Much larger number of genes were selected
by LMe models M1, M2, M3, and M4. The largest num-
ber of genes was identified by M3 implying that M3 is
more powerful method than other LMe models. How-
ever, the results may contain false positive errors. In
Subsection Simulation Study, we investigate this issue
through a simulation study and show that M3 controls
Type I error rate well.
Now, we focus on comparing the results. For simpli-
city, we consider LMe model M3 only for summarizing
the LMe models. Figure 1 shows the number of the sig-
nificant genes identified by meta-analysis, two-stage
ANOVA model, and LMe model M3 when FDR is 1%.
The number of common genes selected by all three
methods was only 16. Among them 9 genes are known
and Table 3 summarizes their characteristics. The num-
ber of common genes selected by two-stage ANOVA
model and meta-analysis was 22. On the other hand, the
numbers of the common genes selected by LMe with
others are small.
The number of genes identified only by M3 was 183 in
the Figure 1 Some genes have been found to be related
with liver disorders (BChE, C6, C9, CAP2, CDKN2A,
CtBP, Cul4A, Gab1, Id1, NTRK1, PSG1, and PSMG).
HChE was shown to exhibit highly elevated aryl acylami-
dase activity (AAA). The absolute levels of AAA were
increased as BChE activity decreased while deviating
from normal samples and such deviation was directly
proportional to the severity of the liver disorder [20].
C6 is a component of the complement system, which
plays an important role as a humoral effector system
during inflammation and infection, and consists of more
than 25 components, including regulatory proteins. C6
was shown to late-acting complement proteins that par-
ticipate in the assembly of the membrane attack com-
plex, which causes cell lysis by the formation of pores in
the cell membrane of certain microorganisms. [21]. C9
was related to the medication of tumor PDT by photo-
sensitizer Photofrin using mouse Lewis lung carcinoma
(LLC) model [22]. Cyclase-associated protein 2 (CAP2)
was listed as an up-regulated gene in early hepatocellu-
lar carcinoma (HCC) [23]. CDKN2A was reported to be
differentially regulated by methylation between normal
Table 2 Genes that are identified as differentially







M1 M2 M3 M4 M5
1% 57 46 119 184 205 124 37
5% 197 145 214 543 589 375 114
10 % 303 203 339 879 978 740 181











Figure 1 Number of genes that are identified by meta-analysis,
two-stage ANOVA, and LMe model M3 when FDR is controlled
by 1%
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tissue and adjacent tissue but high levels in HCC [24].
C-terminal binding protein (CtBP) was reported to
relate with INK4A/ARF tumor suppressor gene. The
INK4A/ARF tumor suppressor locus is frequently inacti-
vated in HCC. Inhibition of cell invasion by p19Arf was
dependent on its C-terminal binding protein (CtBP)
[25]. The Cul4A gene is amplified in human breast and
liver cancers, and loss-of-function of Cul4 results in the
accumulation of the replication licensing factor CDT1 in
Caenorhabditis elegans embryos and ultraviolet (UV)-
irradiated human cells [26].
Gab1 was reported to be related with hepatic insulin
action. Deletion of Gab1 in the liver leads to enhanced
glucose tolerance and improved hepatic insulin action.
It was also shown that association of Gab1 adaptor pro-
tein and Shp2 tyrosine phosphatase is a critical event at
the early phase of liver regeneration [27,28]. Id1 was
identified as TGF-b/ALK1/Smad1 target gene in HSCs
and represents a critical mediator of transdifferentiation
that might be involved in hepatic fibrogenesis. Trans-
forming growth factor (TGF)-b is critically involved in
the activation of hepatic stellate cells (HSCs) that occurs
during the process of liver damage, for example, by alco-
hol, hepatotoxic viruses, or aflatoxins [29,30]. NTRK1
was reported to be a favorable neuroblastoma (NB)
genes. NB is a common pediatric solid tumor that exhi-
bits a striking clinical bipolarity: favorable and unfavor-
able. High-level expression of NTRK1 predicts favorable
NB outcome and inhibits growth of unfavorable NB
cells [31]. PSG1 was reported to an up-regulated gene in
a fetal liver [32]. PSMG was reported to significantly ele-
vated expression in HCC [33].
Simulation study
In order to evaluate the proposed methods, we simu-
lated the two sets of microarray data and then per-
f o r m e dt h ei n t e g r a t e da n a l y s i sb yu s i n gt h ep r o p o s e d
LMe method as well as other methods. For simplicity,
we assume the log-transformed ratio of two intensities
are normally distributed. To mimic the liver cancer
microarray data, we assume that a pair of microarrays
are obtained from the same patient. The first microarray
data set consists of 60 microarrays from 30 patients and
the second data set consists of another 60 microarrays
from 30 patients. Suppose that two microarrays from
t h es a m ep a t i e n ta r ef r o md i f f e r e n tg r o u p s ,s a yf r o m
tumor and control tissues. The main objective of the
analysis is to identify the DEGs between two groups.
We assume the number of genes in each microarray is
30 among which the six genes (20%) are truly differen-
tially expressed: three genes are over-expressed and the
other three genes are under-expressed in the tumor tis-
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where bDl represents a fixed effect of the difference
between two data sets and bTl represents a fixed effect
for difference of expression levels between tumor and
control tissues. The values of bTls are 1.5 for l = 1, ..., 3,
and -1.5 for l = 4, ..., 6, respectively, and zero for l =7 ,
…, 30. The values of bDl are randomly determined by
generating random variables from the standard normal
distribution. Errors are also generated from the normal
distribution with mean 0 and variance s
2 = 0.5
2.
For the random effect bhikl we assume three types of
covariance matrix corresponding to Types 1, 2, and 3
defined in Section Types of Covariance Structure. For
T y p e1 ,t h ec o v a r i a n c em a t r i xbil=(b1iTl, b1iCl, b2iTl,
b2iCl)
T is given by


































We set values of parameters as s11 =1 ,s12 =2 ,s21 =
1.5, and s22 = 2.5. In addition, the correlation parameter
Table 3 Common genes detected by meta-analysis, two-stage ANOVA model, and LMe M3 model when FDR is
controlled by 1% (9 known genes)
Unigene ID Description
Hs.82084 Integrin beta 3 binding protein (beta3-endonexin) (ITGB3BP), mRNA
Hs.514 Cyclin H (CCNH), mRNA
Hs.167529 Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 9 (CYP2C9), mRNA
Hs.117367 Solute carrier family 22 (organic cation transporter), member 1 (SLC22A1), mRNA
Hs.54900 Serologically defined colon cancer antigen 1 (SDCCAG1), mRNA
Hs.80756 Betaine-homocysteine methyltransferase (BHMT), mRNA
Hs.8765 RNA helicase-related protein (RNAHP), mRNA
Hs.755990 Haptoglobin (HP), mRNA
Hs.35101 Proline-rich Gla (G-carboxyglutamic acid) polypeptide 2 (PRRG2), mRNA
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Page 5 of 8between tumor and control tissues are set as 0, 0.2, and
0.4. For Type 2, two variance parameters are set as s1 =
2.5 and s2 = 1, and the correlation parameters are set as
0, 0.2, and 0.4 as Type 1. Finally, for Type 3, two var-
iance parameters are set as s1 = 2.5 and s2 = 1. For the
detailed information of the covariance structure, see
Table 4.
For the simulated data sets, we perform the analyses
using the meta-analysis, the two-stage ANOVA model
and five LMe models. We fit this LMe model by assum-
ing that bil has the covariance structure of Types 1 to 4.
These four models are denoted by M1, M2, M3, and
M4, respectively. The last LMe model M5 is the one
assuming no random effects, which is expected to pro-
vide similar results to the two-stage ANOVA model.
Table 5 shows powers and FDRs from 1,000 simu-
lated data sets. The threshold value q was 0.05. Genes
having ordered q values smaller than 0.05 were identi-
fied as DEGs. Note that there are 6 true significant
genes and 24 null genes. The empirical FDR values
were computed as the number of false significant genes
from 24 null genes divided by the total number of sig-
nificant genes. The empirical power was computed as
the number of significant genes among the 6 true
genes divided by 6.
When r was zero, powers and FDRs showed very con-
sistent results for all methods, although the variances of
tumor tissue and control tissue are assumed to be differ-
ent. This means all methods perform similarly when the
correlation between tumor and control tissues does not
exist.
Table 5 summarizes the simulation results for Type 1
covariance matrix. In general, meta-analysis, two-stage
ANOVA model analysis, and M5 provided similar
results in powers and FDRs. On the other hand, other
LMe models provided quite different results. For exam-
ple, the FDRs tend to be larger but maintain 5% level
approximately except for M1. Powers of LMe models
tend to be much larger than meta-analysis and two-
stage ANOVA model analysis. Among the five LMe
models, M1 and M5 provide distinct results from the
other three models M2, M3, and M4.
It is interesting to note that the performance of each
method depends on the value of r. For meta-analysis,
two-stage ANOVA, and M5, the powers decrease as r
increases. On the other hand, the powers of LMe mod-
els M1 to M4 increase. These tendencies illustrate that
meta-analysis and two-stage ANOVA do not handle
correlations efficiently as LMe models do.
FDRs of LMe models, M2, M3, and M4 are slightly
larger than 0.05. However, the FDR of M1 is much lar-
ger than 0.05, especially when r is close to zero. Thus,
M1 is not appropriate to use when there is no correla-
tion between tumor and control tissues.
Table 5 also summarizes the simulation result for the
Type 2 covariance matrix showing similar patterns with
those of Type 1 except that the results are less sensitive
to r. In summary, meta-analysis, ANOVA model analy-
sis, and M5 provided similar results in powers and
FDRs. On the other hand, other LMe models provided
quite different results. Among the five LMe models, M1
and M5 provided distinct results from the other three
LMe models. The powers of LMe models M1 to M4 are
larger than meta-analysis, ANOVA, and M5. Although
M1 has the largest power, it also shows the largest FDR.
Finally, Table 5 also summarizes the simulation result
for the Type 3 covariance matrix. Though correlation
parameter r was not considered in this case, the correla-
tion between tumor tissue and control tissue of same
patient was assumed by the shared random parameter bhil.
The results of simulated data under Type 3 are quite dif-
ferent from those obtained from Types 1 and 2. That is, all
LMe models, M1, M2, M3, and M4 show extremely good
performance. The powers are all 1 and FDRs are well-con-
trolled around 0.05. LMe models work very well for this
high correlation case. On the other hand, meta-analysis,
ANOVA, and M5 performed worse. Among these, meta-
analysis showed a slightly better performance. It is prob-
ably due to the fact that the meta-analysis allows different
variances between two data sets, while others do not.
Discussion
The LMe model is much more flexible than meta-analy-
sis. One of the main limitations of meta-analysis is
that it cannot handle the sample-specific covariates
Table 4 Setting for random effects bhikl
Type random effects of
subject
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mean difference between tumor tissue and control tissue
[14]. Meta-analysis requires data are homogeneous
within the data set, although data may be heterogeneous
across data sets. For example, when there is sex infor-
mation in data, the effect-size statistic cannot account
for the sex effect directly. On the other hand, LMe mod-
els can handle individual specific covariates easily. In
microarray studies, many researchers want to account
for the individual characteristics in the analysis by
including them as controlling variables. For example,
the covariates such as age, sex, tumor stage, and weight
might be important controlling variables. These covari-
ates are usually sample-specific and differ across
samples.
When there are no random effects, the LMe models
become equivalent to the ANOVA models. The hetero-
geneity among data sets is only represented by the fixed
effects. When heterogeneity among data sets is small,
the ANOVA model can easily handle the variability
among the data sets. However, when data sets have high
variability and contain the correlated data, the addition
of only fixed effects may not be satisfactory. In this case,
the LMe model is more appropriate to analyze data sets,
because it can model the heterogeneous variance and
correlation structure more appropriately. The proposed
LMe model is capable of handling heterogeneous covar-
iance structures by allowing for various random effects.
When the data set contains paired and non-paired
microarrays simultaneously, both meta-analysis and
ANOVA model approaches cannot handle them appro-
priately. For example, the meta-analysis and the ANOVA
analysis treated paired microarrays as independent micro-
arrays. On the other hand, the proposed LMes can han-
dle appropriately the correlation between the paired
microarrays.
Finally, note that the proposed LMe model is valid when
the normality assumption holds. We do not expect this
assumption to hold for real microarray data. However, we
expect the assumption is decreased when sufficiently large
number of microarrays were combined. In future studies,
we will develop permutation tests for the LMe models
which do not require any distributional assumption.
Conclusion
We proposed the LMe model for the integrated analysis
of microarray data to identify DEGs in the presence of
many controlling variables. We analyzed the liver cancer
microarray data set and simulated microarray data to
evaluate the performance of the integration methods.
LMe models except M1 maintained FDRs approxi-
mately. Powers of LMe models except M5 tended to be
much larger than meta-analysis and two-stage ANOVA
model analysis. These tendencies illustrated that meta-
analysis and two-stage ANOVA do not handle correla-
tions efficiently as LMe models do.
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